Identification of a new HLA-A*0201-restricted cryptic epitope from CYP1B1

International Journal of Cancer

Volumn 115, Issue 2, 2005, Pages 333-336

  Maecker, Britta ^a,b   Von Bergwelt Baildon, Michael S ^a,c   Sherr, David H ^d   Nadler, Lee M ^a   Schultze, Joachim L ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cryptic; CYP1B1; Epitope; Immunotherapy; Tumor antigen

Indexed keywords

CD40 ANTIGEN; CYTOCHROME P450 1B1; EPITOPE; HLA A ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE ACTIVATION; CANCER PATIENT; CELL KILLING; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; GENE TARGETING; HALF LIFE TIME; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; PRIORITY JOURNAL; PROTEIN BINDING; SOLID TUMOR; T LYMPHOCYTE; THYMUS; TUMOR CELL LINE; TUMOR IMMUNITY;

ALGORITHMS; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD40; ANTIGENS, NEOPLASM; ARYL HYDROCARBON HYDROXYLASES; B-LYMPHOCYTES; CYTOCHROME P-450 ENZYME SYSTEM; EPITOPES; HALF-LIFE; HLA-A ANTIGENS; HUMANS; LYMPHOMA; MULTIPLE MYELOMA; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 17844407958     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20906     Document Type: Article

References (19)

1. Maecker B, Sherr DH, Vonderheide RH, von Bergwelt-Baildon MS, Hirano N, Anderson KS, Xia Z, Butler MO, Wucherpfennig KW, O'Hara C, Cole G, Kwak SS, et al. The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells. Blood 2003;102:3287-94.
2. Murray GI, Taylor MC, McFadyen MC, McKay JA, Greenlee WF, Burke MD, Melvin WT. Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res 1997;57:3026-31.
3. Gribben JG, Ryan DP, Beach KJ, Urban RG, Hedley ML, Nealon P, Boyajian R, Nadler LM. A phase 1 trial of the novel DNA vaccine ZYC300 targeting the tumor specific antigen CYP1B1 in advanced malignancies. ASCO Proc 2003:679.
4. Colella TA, Bullock TN, Russell LB, Mullins DW, Overwijk WW, Luckey CJ, Pierce RA, Restifo NP, Engelhard VH. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. J Exp Med 2000;191: 1221-32.
5. Theobald M, Biggs J, Hernandez J, Lustgarten J, Labadie C, Sherman LA. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J Exp Med 1997;185:833-41.
6. Cibotti R, Kanellopoulos JM, Cabaniols JP, Halle-Panenko O, Kosmatopoulos K, Sercarz E, Kourilsky P. Tolerance to a self-protein involves its immunodominant but does not involve its subdominant adeterminants. Proc Natl Acad Sci (USA) 1994;89:416-20.
7. Nanda NK, Sercarz EE. Induction of anti-self-immunity to cure cancer. Cell 1995;82:13-7.
8. Gross DA, Graff-Dubois S, Opolon P, Cornet S, Alves P, Bennaceur-Griscelli A, Faure O, Guillaume P, Firat H, Chouaib S, Lemonnier FA, Davoust J, et al. High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J Clin Invest 2004;113: 425-33.
9. Valmori D, Fonteneau JF, Lizana CM, Gervois N, Lienard D, Rimoldi D, Jongeneel V, Jotereau F, Cerottini JC, Romero P. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol 1998;160:1750-8.
10. Kyewski B, Rottinger B, Klein L. Making central T-cell tolerance efficient: thymic stromal cells sample distinct self-antigen pools. Curr Top Microbiol Immunol 2000;251:139-45.
11. Schultze JL, Michalak S, Seamon MJ, Dranoff G, Jung K, Daley J, Delgado JC, Gribben JG, Nadler LM. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest 1997;100:2757-65.
12. von Bergwelt-Baildon MS, Vonderheide RH, Maecker B, Hirano N, Anderson KS, Butler MO, Xia Z, Zeng WY, Wucherpfennig KW, Nadler LM, Schultze JL. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood 2002;99:3319-25.
13. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994;152:163-75.
14. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999;50:213-9.
15. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999;10:673-9.
16. Altman JD, Moss PAH, Goulder PJR, Barouch DH, McHeyzer-Williams MG, Bell JI, McMichael AJ, Davis MM. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996;274:94-6.
17. Maecker B, Anderson KS, von Bergwelt-Baildon MS, Weller E, Vonderheide RH, Richardson PG, Schlossman RL, Menezes IA, Xia Z, Munshi NC, Anderson KC, Nadler LM, et al. Viral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma. Br J Haematol 2003;121:842-8.
18. Vonderheide RH, Schultze JL, Anderson KS, Maecker B, Butler MO, Xia Z, Kuroda MJ, von Bergwelt-Baildon MS, Bedor MM, Hoar KM, Schnipper DR, Brooks MW, et al. Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals. Cancer Res 2001;61:8366-70.
19. Molldrem JJ, Lee PP, Wang C, Champlin RE, Davis MM. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res 1999;59:2675-81.